Info

ADVENTRX Pharmaceuticals, Inc. is a biopharmaceutical company focused on in-licensing, developing and commercializing product candidates primarily for the treatment of cancer and infectious disease. The Company is focused primarily on advancing ANX-530 and ANX-514, which are emulsion formulations of marketed chemotherapy drugs. ADVENTRX Pharmaceuticals is also developing ANX-510, or CoFactor, which is a folate-based biomodulator designed to replace leucovorin as the preferred method to enhance the activity and reduce the associated toxicity of cancer chemotherapeutic agent 5-FU (5-fluorouracil). In August 2007, the Company announced that the United States Food and Drug Administration (FDA) has granted fast track designation for ANX-510, or CoFactor injection, which is being investigated in a pivotal Phase III study, with 5-fluorouracil (5-FU) and bevacizumab for the initial treatment of metastatic colorectal cancer.